Telix Pharmaceuticals (TLX) Receivables (2023 - 2026)

Telix Pharmaceuticals (TLX) has reported Receivables for 3 consecutive years, with $130.5 million the latest figure, recorded in Q4 2025.

• In Q4 2025, Receivables rose 40.47% year-over-year to $130.5 million; the TTM figure through Dec 2025 stood at $130.5 million (up 40.47% YoY), while the FY2025 annual figure was $130.5 million, up 40.27% from the prior year.
• Receivables climbed to $130.5 million in Q4 2025 per TLX's latest filing, from $92.9 million in the prior quarter.
• Across five years, Receivables topped out at $130.5 million in Q4 2025 and bottomed at $43.7 million in Q4 2023.
• Historically, Receivables has averaged $89.0 million across 3 years, with a median of $92.9 million in 2024.
• Annual changes were most pronounced in 2024 — Receivables surged 112.53% — and 2025, when it soared 40.47%.
• Telix Pharmaceuticals' Receivables stood at $43.7 million in 2023, then jumped by 112.53% to $92.9 million in 2024, then jumped by 40.47% to $130.5 million in 2025.
• Business Quant data shows TLX's Receivables at $130.5 million in Q4 2025, $92.9 million in Q4 2024, and $43.7 million in Q4 2023.